drugset / Trial / NCT03632135

Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma

NCT03632135

Phase 3 Completed 78 enrolled Cordgenics, LLC
RandomizedParallel-groupQuadruple-blindDiagnostic

Summary

The purpose of this clinical study is to confirm the utility of chemosensitivity tumor testing on cancer stem cells (ChemoID) as a predictor of clinical response in poor prognosis malignant brain tumors such as recurrent glioblastoma (GBM).

Timeline

Start
2018-05-20
Primary completion
2022-06-16
Completion
2023-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule
Subject Etoposide Small molecule
Subject Imatinib Small molecule
Subject Irinotecan Small molecule
Subject Lomustine Small molecule
Subject Temozolomide Small molecule
Subject Vincristine Small molecule
Subject carmustine Small molecule
Subject procarbazine Small molecule

Indications